Profile data is unavailable for this security.
About the company
LifeVantage Corporation is engaged in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products. The Company's dietary supplements include its flagship Protandim family of products, LifeVantage Omega+, ProBio, IC Bright, Rise AM, Reset PM, D3+, Daily Wellness, and PhysIQ Fat Burn and Prebiotic dietary supplements. The Protandim product line includes Protandim NRF1 Synergizer, Protandim Nrf2 Synergizer, and Protandim NAD Synergizer. TrueScience is its line of skin and hair care products and Liquid Collagen. The Company also markets and sells Petandim, its companion pet supplement formulated to combat oxidative stress in dogs, and AXIO, its nootropic energy drink mix. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, Spain, Ireland, Singapore, and the Philippines.
- Revenue in USD (TTM)200.16m
- Net income in USD2.94m
- Incorporated2018
- Employees217.00
- LocationLifeVantage Corp3300 TRIUMPH BLVD, SUITE 700LEHI 84043United StatesUSA
- Phone+1 (801) 432-9000
- Fax+1 (302) 636-5454
- Websitehttps://www.lifevantage.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marinus Pharmaceuticals Inc | 30.26m | -149.24m | 83.18m | 165.00 | -- | -- | -- | 2.75 | -2.66 | -2.66 | 0.5391 | -0.8614 | 0.21 | 0.7508 | 6.98 | 183,412.10 | -103.54 | -49.64 | -131.60 | -57.76 | 90.64 | -- | -493.14 | -518.96 | 2.15 | -11.80 | 6.10 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| I-Mab ADR | -100.00bn | -100.00bn | 88.16m | 220.00 | -- | 0.3751 | -- | -- | -- | -- | -- | 2.91 | -- | -- | -- | -- | -- | -35.51 | -- | -41.43 | -- | -- | -- | -509.54 | -- | -- | 0.00 | -- | 111.86 | -13.65 | 44.45 | -- | -5.95 | -- |
| Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 88.22m | 35.00 | 391.37 | 348.44 | -- | 35.38 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 23.10m | -27.21m | 90.59m | 176.00 | -- | 10.04 | -- | 3.92 | -2.03 | -2.03 | 1.72 | 0.6731 | 0.3577 | 0.8917 | 2.39 | 131,250.00 | -41.56 | -34.75 | -62.38 | -46.91 | 56.81 | 55.98 | -116.17 | -153.72 | 2.36 | -- | 0.6718 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| Rockwell Medical Inc | 94.37m | -4.77m | 121.87m | 237.00 | -- | 5.31 | -- | 1.29 | -0.169 | -0.169 | 3.21 | 0.7573 | 2.07 | 13.97 | 11.61 | 398,194.10 | -10.48 | -46.29 | -16.25 | -65.38 | 13.44 | 4.66 | -5.06 | -36.51 | 1.60 | -1.84 | 0.3144 | -- | 14.84 | 5.69 | 54.82 | -- | 76.21 | -- |
| Assertio Holdings Inc | 132.19m | -345.11m | 123.94m | 53.00 | -- | 0.9378 | -- | 0.9376 | -4.11 | -4.11 | 1.44 | 1.39 | 0.3862 | 1.27 | 3.24 | 2,494,076.00 | -100.82 | -21.51 | -134.56 | -32.05 | 72.12 | 88.68 | -261.08 | -62.10 | 1.51 | -- | 0.2266 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
| LifeVantage Corp | 200.16m | 2.94m | 126.54m | 217.00 | 45.11 | 4.88 | 19.41 | 0.6322 | 0.2248 | 0.2248 | 15.51 | 2.08 | 3.17 | 2.66 | 87.77 | 922,414.80 | 4.65 | 9.95 | 6.95 | 15.55 | 79.30 | 81.45 | 1.47 | 3.08 | 1.01 | -- | 0.00 | 26.95 | -6.20 | -2.40 | 15.63 | -16.94 | -2.18 | -- |
| OptiNose Inc | 75.06m | -40.91m | 128.16m | 132.00 | -- | -- | -- | 1.71 | -0.3479 | -0.3479 | 0.6195 | -0.2863 | 0.6309 | 0.7909 | 3.50 | 568,621.20 | -34.39 | -48.25 | -199.84 | -98.95 | 89.92 | 86.96 | -54.50 | -131.66 | 3.59 | -0.8537 | 1.52 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| Elutia Inc | 24.99m | -70.10m | 131.47m | 54.00 | -- | -- | -- | 5.26 | -3.05 | -2.86 | 1.12 | -2.28 | 0.5303 | 2.32 | 5.08 | 462,722.20 | -148.77 | -42.93 | -1,212.93 | -79.34 | 42.46 | 43.32 | -280.53 | -64.16 | 0.6842 | -0.6561 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 138.32m | 217.00 | -- | 1.02 | -- | 43.51 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| Hongchang International Co Ltd | 4.65m | -292.22k | 140.08m | 8.00 | -- | 3.57 | -- | 30.13 | -0.0006 | -0.0006 | 0.0093 | 0.0757 | 0.1647 | 5.02 | 8.74 | -- | -0.8827 | -7.98 | -0.9331 | -10.94 | 3.92 | 11.47 | -5.36 | -64.88 | 3.77 | -- | 0.2642 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| Eton Pharmaceuticals Inc | 31.38m | -6.69m | 152.69m | 30.00 | -- | 11.30 | -- | 4.87 | -0.2596 | -0.2596 | 1.22 | 0.5229 | 1.00 | 8.82 | 7.89 | 1,046,033.00 | -21.31 | -46.22 | -38.27 | -58.20 | 59.48 | 72.16 | -21.31 | -76.86 | 1.28 | -- | 0.2571 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| Biostem Technologies Inc | 131.44m | 7.87m | 158.96m | 67.00 | 29.17 | 8.78 | 19.66 | 1.21 | 0.3346 | 0.3346 | 7.31 | 1.11 | 2.80 | 7.41 | 3.35 | -- | 16.78 | -- | 107.11 | -- | 94.73 | -- | 5.98 | -- | 1.20 | 15.52 | 0.2012 | -- | -- | -- | -- | -- | -- | -- |
| Lifecore Biomedical Inc | 128.26m | 9.33m | 160.67m | 524.00 | 35.09 | 14.05 | 8.83 | 1.25 | 0.1482 | 0.2318 | 3.83 | 1.76 | 0.5055 | 2.14 | 4.26 | 244,774.80 | 3.68 | -5.91 | 4.35 | -8.33 | 32.63 | 31.01 | 7.27 | -19.16 | 1.06 | 0.2373 | 0.6923 | -- | 24.20 | -25.46 | 114.53 | 34.47 | -16.72 | -- |
Data as of Sep 19 2024. Currency figures normalised to LifeVantage Corp's reporting currency: US Dollar USD
25.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 30 Jun 2024 | 855.12k | 6.85% |
| Sudbury Capital Management LLCas of 26 Feb 2024 | 749.33k | 6.01% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 495.25k | 3.97% |
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 277.80k | 2.23% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 223.97k | 1.80% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 198.57k | 1.59% |
| Geode Capital Management LLCas of 30 Jun 2024 | 122.84k | 0.98% |
| Bridgeway Capital Management LLCas of 30 Jun 2024 | 110.77k | 0.89% |
| Empowered Funds LLCas of 30 Jun 2024 | 78.86k | 0.63% |
| Perkins Capital Management, Inc.as of 30 Jun 2024 | 76.11k | 0.61% |
More ▼
Data from 30 Jun 2024 - 01 Jul 2024Source: FactSet Research Systems Inc.
